Zevra Therapeutics (ZVRA) Assets Average (2015 - 2026)

Zevra Therapeutics (ZVRA) has 12 years of Assets Average data on file, last reported at $281.7 million in Q1 2026.

• Quarterly Assets Average rose 60.56% year-over-year to $281.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $281.7 million (up 60.56% YoY) and the FY2025 annual result came in at $231.4 million, up 32.07% from the prior year.
• Assets Average grew to $281.7 million in Q1 2026, from $277.4 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $281.7 million in Q1 2026 to a low of $61.9 million in Q2 2022.
• A 5-year average of $168.0 million and a median of $161.8 million in 2024 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2022 — Assets Average plunged 45.98% — and 2026, when it jumped 60.56%.
• Tracing ZVRA's Assets Average over 5 years: stood at $117.2 million in 2022, then surged by 32.77% to $155.7 million in 2023, then climbed by 18.75% to $184.8 million in 2024, then soared by 50.09% to $277.4 million in 2025, then increased by 1.53% to $281.7 million in 2026.
• The last three Assets Average figures came in at $281.7 million (Q1 2026), $277.4 million (Q4 2025), and $263.2 million (Q3 2025), per Business Quant data.